By Chris Wack
Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations.
The medical-device company's stock was up 16%, to $3.83, midday Monday.
Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for.
For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million.
Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024.
Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 13, 2025 13:52 ET (18:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.